CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Irbesartan treatmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00317915
NCT00317915Phase 3Completed
CompareCT.gov

The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)

Steno Diabetes Center Copenhagen·interventional·Posted Apr 25, 2006·Updated Apr 25, 2006

In Brief

A Phase 3 clinical trial evaluating Irbesartan treatment for Type 2 Diabetes and 2 related conditions. Completed.

Detailed Summary

The aim of this multicenter, doubleblind, randomized study was to investigate the renoprotective effect of irbesartan treatment in patients with type 2 diabetes and microalbuminuria (a precursor of diabetic kidney disease). 590 patients were randomized to a median 24 months of treatment with 300 mg irbesartan once daily, 150 mg irbesartan once daily or placebo. Time to development of overt nephropathy, defined by persistent proteinuria, was the primary outcome measure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Microalbuminuria, Hypertension
Countries--
CollaboratorsBristol-Myers Squibb, Sanofi-Synthelabo

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2006
TodayJul 2, 2026
Posted 20.2 years ago

Interventions

Irbesartan treatmentdrug